Literature DB >> 16432193

Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure.

Soraya Abouzahr1, Georges Bismuth, Catherine Gaudin, Oliver Caroll, Peter Van Endert, Abdelali Jalil, Jean Dausset, Isabelle Vergnon, Catherine Richon, Audrey Kauffmann, Jérôme Galon, Graca Raposo, Fathia Mami-Chouaib, Salem Chouaib.   

Abstract

To investigate tumor resistance to T cell lysis, a resistant variant was selected after specific cytolytic T lymphocytes (CTL) selection pressure. Although the resistant variant triggered perforin and granzyme B transcription in specific CTLs, as well as their degranulation, it exhibited a dramatic resistance to cytotoxic T cell killing. It also displayed strong morphological changes with alterations of the actin cytoskeleton. Electron microscopy analysis revealed a loosen interaction between CTLs and the resistant variant despite the formation of apparently normal conjugates. Transcriptional profiling identified a gene expression signature that distinguished sensitive from resistant tumor targets. More notably, we found that actin-related genes ephrin-A1 and scinderin were overexpressed in resistant target. Silencing of these genes using RNA interference resulted in a restoration of normal cell morphology and a significant attenuation of variant resistance to CTL killing. Our present study shows that a shift in cytoskeletal organization can be used, by tumor cells, as a strategy to promote their resistance after CTL selection pressure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16432193      PMCID: PMC1360579          DOI: 10.1073/pnas.0510454103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

Review 1.  Eph receptors and ephrin ligands: embryogenesis to tumorigenesis.

Authors:  V C Dodelet; E B Pasquale
Journal:  Oncogene       Date:  2000-11-20       Impact factor: 9.867

2.  IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.

Authors:  V Shankaran; H Ikeda; A T Bruce; J M White; P E Swanson; L J Old; R D Schreiber
Journal:  Nature       Date:  2001-04-26       Impact factor: 49.962

Review 3.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

Review 4.  Natural selection of tumor variants in the generation of "tumor escape" phenotypes.

Authors:  Hung T Khong; Nicholas P Restifo
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

5.  Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer.

Authors:  Tetsuya So; Mitsuhiro Takenoyama; Makiko Mizukami; Yoshinobu Ichiki; Masakazu Sugaya; Takeshi Hanagiri; Kenji Sugio; Kosei Yasumoto
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

6.  Evidence for in situ expansion of diverse antitumor-specific cytotoxic T lymphocyte clones in a human large cell carcinoma of the lung.

Authors:  H Echchakir; I Vergnon; G Dorothée; D Grunenwald; S Chouaib; F Mami-Chouaib
Journal:  Int Immunol       Date:  2000-04       Impact factor: 4.823

7.  Reduced expression of EphrinA1 (EFNA1) inhibits three-dimensional growth of HT29 colon carcinoma cells.

Authors:  Lyka Potla; Erwin R Boghaert; Douglas Armellino; Philip Frost; Nitin K Damle
Journal:  Cancer Lett       Date:  2002-01-25       Impact factor: 8.679

8.  Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems.

Authors:  N J Caplen; S Parrish; F Imani; A Fire; R A Morgan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

9.  EphrinA1-induced cytoskeletal re-organization requires FAK and p130(cas).

Authors:  Nigel Carter; Tetsuya Nakamoto; Hisamaru Hirai; Tony Hunter
Journal:  Nat Cell Biol       Date:  2002-08       Impact factor: 28.824

10.  Suppression of tumorigenicity in breast cancer cells by the microfilament protein profilin 1.

Authors:  J Janke; K Schlüter; B Jandrig; M Theile; K Kölble; W Arnold; E Grinstein; A Schwartz; L Estevéz-Schwarz; P M Schlag; B M Jockusch; S Scherneck
Journal:  J Exp Med       Date:  2000-05-15       Impact factor: 14.307

View more
  21 in total

Review 1.  Immunological Consequences of Epithelial-Mesenchymal Transition in Tumor Progression.

Authors:  Peter J Chockley; Venkateshwar G Keshamouni
Journal:  J Immunol       Date:  2016-08-01       Impact factor: 5.422

2.  Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs.

Authors:  Ali R Jazirehi; James S Economou
Journal:  Mol Cancer Ther       Date:  2012-04-24       Impact factor: 6.261

3.  Histone deacetylase inhibitor sensitizes apoptosis-resistant melanomas to cytotoxic human T lymphocytes through regulation of TRAIL/DR5 pathway.

Authors:  Ali R Jazirehi; Siavash K Kurdistani; James S Economou
Journal:  J Immunol       Date:  2014-03-17       Impact factor: 5.422

4.  Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Authors:  Lionel Apetoh; Mark J Smyth; Charles G Drake; Jean-Pierre Abastado; Ron N Apte; Maha Ayyoub; Jean-Yves Blay; Marc Bonneville; Lisa H Butterfield; Anne Caignard; Chiara Castelli; Federica Cavallo; Esteban Celis; Lieping Chen; Mario P Colombo; Begoña Comin-Anduix; Georges Coukos; Madhav V Dhodapkar; Glenn Dranoff; Ian H Frazer; Wolf-Hervé Fridman; Dmitry I Gabrilovich; Eli Gilboa; Sacha Gnjatic; Dirk Jäger; Pawel Kalinski; Howard L Kaufman; Rolf Kiessling; John Kirkwood; Alexander Knuth; Roland Liblau; Michael T Lotze; Enrico Lugli; Francesco Marincola; Ignacio Melero; Cornelis J Melief; Thorsten R Mempel; Elizabeth A Mittendorf; Kunle Odun; Willem W Overwijk; Anna Karolina Palucka; Giorgio Parmiani; Antoni Ribas; Pedro Romero; Robert D Schreiber; Gerold Schuler; Pramod K Srivastava; Eric Tartour; Danila Valmori; Sjoerd H van der Burg; Pierre van der Bruggen; Benoît J van den Eynde; Ena Wang; Weiping Zou; Theresa L Whiteside; Daniel E Speiser; Drew M Pardoll; Nicholas P Restifo; Ana C Anderson
Journal:  Oncoimmunology       Date:  2015-02-25       Impact factor: 8.110

5.  Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction.

Authors:  Ali R Jazirehi; Stavroula Baritaki; Richard C Koya; Benjamin Bonavida; James S Economou
Journal:  Cancer Res       Date:  2010-12-15       Impact factor: 12.701

6.  hSMG-1 is a granzyme B-associated stress-responsive protein kinase.

Authors:  Franck Meslin; Ahmed Hamaï; Bernhard Mlecnik; Filippo Rosselli; Catherine Richon; Abdelali Jalil; Gregory Wemhoff; Jerome Thiery; Jerome Galon; Salem Chouaib
Journal:  J Mol Med (Berl)       Date:  2011-02-08       Impact factor: 4.599

7.  Differential effects of a saturated and a monounsaturated fatty acid on MHC class I antigen presentation.

Authors:  S R Shaikh; D Mitchell; E Carroll; M Li; J Schneck; M Edidin
Journal:  Scand J Immunol       Date:  2008-07       Impact factor: 3.487

8.  Gene expression signature for spontaneous cancer regression in melanoma pigs.

Authors:  Florian Rambow; Guillaume Piton; Stephan Bouet; Jean-Jaques Leplat; Sylvain Baulande; Angelique Marrau; Mark Stam; Vratislav Horak; Silvia Vincent-Naulleau
Journal:  Neoplasia       Date:  2008-07       Impact factor: 5.715

Review 9.  Tumor immunoediting and immunosculpting pathways to cancer progression.

Authors:  Jennifer M Reiman; Maciej Kmieciak; Masoud H Manjili; Keith L Knutson
Journal:  Semin Cancer Biol       Date:  2007-06-26       Impact factor: 15.707

10.  Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome In Vitro by Pharmacological Inhibition of Cdc42-Induced Actin Cytoskeleton Remodeling.

Authors:  Hannah Wurzer; Liza Filali; Céline Hoffmann; Max Krecke; Andrea Michela Biolato; Jérôme Mastio; Sigrid De Wilde; Jean Hugues François; Anne Largeot; Guy Berchem; Jérôme Paggetti; Etienne Moussay; Clément Thomas
Journal:  Front Immunol       Date:  2021-05-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.